Nectar Lifesciences P/E Ratio
Nectar Lifesciences P/E ratio. Nectar Lifesciences (NECLIFE) P/E ratio is not applicable — EPS (TTM) ₹-13.40, 5 consecutive loss quarters. See Healthcare peers with valid P/E ratios below.
P/E Ratio Status
N/A
Loss Making
Company is currently reporting losses
P/E Ratio Not Applicable
Company has been reporting losses for 5 consecutive quarters. P/E ratio cannot be calculated for loss-making companies.
Consecutive Loss Quarters: 5
Current EPS: ₹-13.40
Recent Quarterly Performance
| Quarter | EPS (₹) | Net Profit (₹ Cr) | Status |
|---|---|---|---|
| Mar 2026 | -3.38 | -68 | Loss |
| Jun 2026 | -0.79 | -15 | Loss |
| Sept 2025 | -7.85 | -176 | Loss |
| Mar 2025 | -5.80 | -130 | Loss |
| Jun 2025 | -2.82 | -63 | Loss |
| Dec 2025 | 0.64 | 14 | Profit |
| Sept 2024 | 0.25 | 6 | Profit |
| Mar 2024 | 0.03 | 1 | Profit |
Healthcare Peers with Valid P/E Ratios — NECLIFE Comparison
Healthcare sector average P/E 56.19, median 32.5 — NECLIFE excluded (negative EPS).
Sector Average PE
56.19
Sector Median PE
32.5
Lowest PE
2.04
Profitable Companies
200
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Sunrest Lifescience | SUNREST | 2.04 | ₹65 | Low |
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Phaarmasia | PHRMASI | 3.41 | ₹63 | Low |
| Sun Pharma Advanced Rese… | SPARC | 3.98 | ₹6,206 | Low |
| Dipna Pharmachem | DPL | 4.57 | ₹12 | Low |
| JFL Life Sciences | JFLLIFE | 4.88 | ₹66 | Low |
| GKB Ophthalmics | GKB | 5.88 | ₹32 | Low |
| Kabra Drugs | KABRADG | 6.09 | ₹44 | Low |
| Royal Sense | ROYAL | 6.58 | ₹47 | Low |
| Colinz Laboratories | COLINZ | 6.62 | ₹18 | Low |
Related Analysis
- For live price, revenue and the complete fundamental profile, see NECLIFE share price screener.
- Examine NECLIFE quarterly performance for recent quarterly revenue, profit and EPS trends.
- Also explore Nectar Lifesciences share price performance to track price trends across different timeframes.